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The first “close encounter” between the
fields of chemokines and HIV occurred
in the late spring of 1995, when my
group at NCI’s Laboratory of Tumor Cell
Biology (LTCB) received from Harvard
Microchemistry and Proteomics the amino
acid sequences of three peptide fragments
from an HPLC-purified fraction that we
had submitted a few weeks earlier. The
sequences showed a perfect match with the
human chemokine RANTES/CCL5. The
fraction had been isolated from the cul-
ture supernatant of an immortalized T-
cell clone (FC36.22) producing the elu-
sive “CD8-derived HIV-suppressive factor”
whose existence had been postulated by Jay
Levy’s group at UCSF since 1986 (1), but
whose identity had remained enigmatic for
nearly a decade.
Two years earlier, when Fiorenza Coc-
chi, at that time a post-doctoral fellow
from Milan, Italy, had approached me with
the proposal to embark on the quest for
the “Levy factor,” my first reaction had
been anything but enthusiastic. Not that
I had any doubt about the significance of
identifying an endogenous factor that was
believed to help HIV-infected individuals
remain asymptomatic by suppressing the
virus in a non-cytolytic fashion (2). On sev-
eral occasions, we had heard Levy illustrate
his model, and Bob Gallo, our inspiring
lab chief at the LTCB, had often remarked
on the importance of resolving this long-
standing riddle. However, all attempts to
identify the factor until then had failed
in the midst of confusion among differ-
ent designations, experimental models, and
mechanistic hypotheses (3), and skepticism
about the very existence of such factor
was on the rise. Furthermore, my labo-
ratory’s focus was on pathogenesis, with
very limited expertise in protein chem-
istry. And so, we concurred to give it a
try, but I made it clear that we would
soon drop the project unless we could
come up with a robust and reproducible
experimental system to justify a long-term
commitment.
The original phenomenological
observation on the non-cytolytic HIV-
suppressive activity of CD8+ T cells was
made by Chris Walker and Jay Levy in the
mid-80s while they were attempting to
increase the rate of HIV-1 isolation from
asymptomatic seropositive individuals.
They found that removal of CD8+ T cells
from the cultures greatly enhanced their
odds of success; when autologous CD8+ T
cells were added back to the cultures, virus
replication was again suppressed but the
number of CD4+ T cells remained con-
stant, thus ruling out a classic “cytotoxic
T-lymphocyte” effect (1). In subsequent
years, the same group went on to show
that the activity was not bound to MHC
restriction and was at least in part mediated
by a soluble factor – initially nicknamed
“CAF”– that was diffusible through a semi-
permeable membrane (4). Moreover, they
established a correlation between the levels
of CAF production and the asymptomatic
state of HIV-1 infection (2), corroborating
the clinical significance of this uncon-
ventional CD8+ T-cell activity. Despite
intensive efforts, however, no progress
toward the identification of the factor was
made over the following years. One of
the key challenges was the extremely low
level of factor that could be rescued from
primary CD8+ T-lymphocyte cultures,
further complicated by marked donor–
donor variability. Yet, Levy insisted that the
activity was an exclusive product of pri-
mary CD8+ T cells and a specific attribute
of HIV-seropositive individuals (4), which
posed major challenges for production
scale-up.
We reasoned that the first critical step
to tackle this project was to devise a high-
yield and reproducible cellular source for
the factor, and we began testing primary
and immortalized CD8+ T cells from both
seropositive and seronegative donors under
diverse conditions of activation and cul-
ture. The LTCB was an ideal site in this
respect because a major focus for over two
decades had been the optimization of T-
cell growth conditions, culminating in the
discovery of “T-cell growth factor,” sub-
sequently named interleukin-2, by Doris
Morgan, Frank Ruscetti, and Gallo in 1976
(5), and the isolation of the first human
retrovirus, HTLV-1, which can immortalize
both CD4+ and CD8+ T cells ex vivo,
by Bernie Poiesz and Gallo in 1980 (6).
Thus, besides testing primary CD8+ T
cells, we derived CD8+ T-cell lines immor-
talized with HTLV-1 or its little brother,
HTLV-2, and dug deep into the freez-
ers in search for every vintage CD8+ T-
cell line that we could test. Among the
many cells that we screened was 67-I,
an HTLV-I-immortalized clone obtained a
few years earlier by Anita DeRossi at the
LTCB (7), which eventually turned out to
be the key to our success. Derived from
the peripheral blood of a healthy blood
donor, 67-I retained many features of pri-
mary CD8+ T cells, but unlike the latter
it provided a stable and scalable source
of soluble factors and was adaptable to
grow under serum-free culture conditions,
which would eventually simplify purifica-
tion of the factor.
In parallel to developing an efficient
“factor factory,” a second critical need was
to establish a highly standardized read-
out system for the quantitative deter-
mination of antiviral activity. Again, it
was essential to overcome the inconsis-
tencies of primary cells and, even worse,
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of poorly characterized endogenous viral
strains harbored by patient-derived CD4+
T cells (1, 2). Thus, we embarked in the
screening of a wide panel of target cells and
viral strains. We eventually opted for PM1,
a CD4+ clone that we had recently derived
from the leukemic T-cell line Hut78,
which featured an uncommon suscepti-
bility to diverse HIV-1 variants, including
laboratory-adapted and primary isolates
with both T-cell and macrophage tropism
(8). Taking advantage of this unique qual-
ity of PM1, we enhanced our chances of
success by entering two divergent HIV-1
variants into our default testing protocol:
a typical laboratory strain, IIIB, adapted
to grow in continuous T-cell lines, and
a macrophage-tropic strain, BaL, passaged
exclusively in primary cells, which shared
many properties with primary HIV-1 iso-
lates. The system was highly standardized
and suitable for high-throughput screen-
ing. But when Fiorenza showed up one
afternoon with the results of the first exper-
iment, we could hardly believe our eyes: the
culture supernatant of 67-I had completely
suppressed the BaL strain, while the IIIB
strain had continued to replicate impas-
sively. At first, we thought it could only be a
technical error, and we decided to indepen-
dently repeat the experiment in separate
laboratories. The results came out a few
days later and again they were stunning: in
both repeats, BaL was completely inhibited,
while IIIB was untouched! Not only did we
have in our hands a powerful and repro-
ducible source of HIV-suppressive factor
but also the unequivocal bias in favor of
the primary-like viral isolate gave us con-
fidence in the specificity of the suppressive
effect.
As we had finally pulled together the
right experimental tools for the biological
side of the project, we set out to iden-
tify a skilled protein chemist who could
plunge into the backbreaking process of
biochemical purification. Thus, we made
contact with Tony DeVico, at that time a
young research associate at ABL, an NIH-
contractor laboratory in Rockville, who
had the necessary know-how and enthusi-
asm to dive into this high-risk/high-reward
endeavor. After discussing multiple strate-
gies, we established a basic purification
protocol, leaving the option open to mod-
ifying it at any time based on the progress
of the project.
Looking backwards, although
“serendipity” is a term commonly used
to describe discoveries in which a “mys-
tery object” remains mysterious until the
epilog of the story, never was in my sci-
entific career an experimental design so
meticulously and systematically planned
ahead in its finest details. This notwith-
standing, we were bound for a string of
false leads and dead ends that put our trust
and determination to serious trial.
Over the next several months, the cycle
was repeated over and over: large volumes
of serum-free culture fluid conditioned by
a high-producer 67-I subclone, FC36.22,
were collected, clarified, concentrated by
size fractionation, and subjected to HPLC
purification using different matrices. Puri-
fied fractions were then individually tested
against HIV-1 BaL in PM1 cells. Many a
cycle was to go “dry,” with no fractions
retaining sufficient activity to justify fur-
ther analysis. Then, a few months down
the road, a first intriguing lead: a bioactive
fraction containing a single peak was sent
for proteomics analysis. Our excitement
was sky-high when the results came back
a few weeks later showing that the frac-
tion contained human insulin-like growth
factor-1 (IGF-1), an immunomodulatory
hormone. We immediately attempted to
validate the lead, but commercial IGF-1
preparations did not show antiviral activity
in our system, and neutralizing antibod-
ies to IGF-1 did not abrogate the activity
in crude FC36.22 supernatants. Thus, the
lead was abandoned even though IGF-1
was later reported to inhibit HIV-1 (9).
After several other “dry” cycles, we stum-
bled upon another candidate factor, which
opened a fascinating new perspective: a
bioactive fraction yielded a fragment iden-
tical to an HTLV-1 protein, suggesting an
intriguing scenario of virus–virus interfer-
ence. Though captivating as this hypothesis
was, the results were not reproducible
using concentrated HTLV-1 fractions and,
besides, the model was incompatible with
the bulk of previous observations made
with HTLV-1-negative patient CD8+ T
cells. We had to move on, and the cycles
resumed.
It was a bright and hot late-spring after-
noon in Milan. One of those days that
give your senses a first savor of the immi-
nent summer: my first one back in Italy
after nine and a half years in Bethesda.
The phone rang in my temporary office in
the new DIBIT building at the San Raffaele
Institute where I was creating my own Lab-
oratory of Human Virology. When I picked
up, Fiorenza’s voice on the other side could
hardly conceal her excitement: “We’ve got
new sequences – she said right off the bat –
It’s RANTES!”. While the call was still on,
I jumped on MEDLINE and crossed the
two keywords: “RANTES” and “HIV.” I hit
“return”and, to my astonishment, the result
was . . . zero! Even just by chance, almost
any two keywords yield at least a half dozen
citations. “Zero” was not only really amaz-
ing but also somewhat frightening. It was
like in those science-fiction movies when
they open a door in a dark empty hallway
to find themselves into the dazzling light
of a totally new dimension: there we were,
all of a sudden projected into the fantastic
world of the chemoattractants!
Of course, having chased several false
leads in the previous months made us
temper our enthusiasm and keep our feet
on the ground. But a few weeks later,
when we received the sequences from a
second bioactive fraction matching 100%
the “sister” chemokine MIP-1α/CCL3, our
adrenalin level had a dramatic jolt. We
knew that this time we were on the right
track. We swiftly ordered a set of recom-
binant proteins and neutralizing antibod-
ies, including those specific for the third
“sister” chemokine, MIP-1β/CCL4, even
though we had not yet received pro-
teomics confirmation for this last mem-
ber of the trio. In early September, we
submitted an article to Science that, in
spite of a single hopeless negativist ref-
eree who raised all sorts of questions
about the past, present, and future rele-
vance of our findings, was rapidly accepted
and appeared in print on December 15,
1995 (10). With an unorthodox move, Sci-
ence heralded our paper with a Commen-
tary by Michael Balter in the December
8 issue (11), concomitant with the pub-
lication in Nature of another candidate
CD8-derived antiviral factor, interleukin-
16 (12). In the paper, we presented con-
clusive evidence that: (i) RANTES, MIP-
1α, and MIP-1β are three potent and spe-
cific endogenous HIV-1 inhibitors; (ii) they
are abundantly produced by both immor-
talized and primary CD8+ T cells; and
(iii) altogether they constitute a major
component of the soluble HIV-suppressive
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activity produced by these cells (10).
For the first time, we were exposing
the “double life” of certain chemokines,
turned overnight from aseptic cellular-
traffic policemen into specific endogenous
virus-busters. One of the greatest sur-
prises in this saga was the realization that
the long-sought-after CD8 anti-HIV fac-
tor in fact, comprises multiple factors,
breaking a central dogma of the origi-
nal model (4). Indeed, evidence continues
to accumulate on the existence of a wide
range of endogenous HIV-suppressive fac-
tors, as illustrated by our recent identifi-
cation of XCL1/lymphotactin as a novel
anti-HIV chemokine produced by CD8+
T cells (13).
The rest of the story is well known.
Almost fictional was the extraordinary
time coincidence whereby <6 months after
the publication of our paper Ed Berger
and his colleagues at the NIAID reported
in Science the first HIV-1 coreceptor,
fusin/CXCR4 (14) – another “serendip-
itous” discovery? – which happened to
be an orphan “chemokine” receptor origi-
nally identified by Bernhard Moser’s group
in Bern (15). Likewise, virtually at the
same time, Phil Murphy’s group at the
NIAID (16) and Marc Parmentier’s group
in Brussels (17) were both characteriz-
ing the same novel “chemokine” recep-
tor (CCR5) specific for RANTES, MIP-1α,
and MIP-1β, which was almost immedi-
ately shown by Berger’s and four other
groups to be the second, physiologically
most relevant, HIV-1 coreceptor (3). Curi-
ously, despite having worked on the same
campus for years, I had never previously
met Ed or Phil, who later became good
friends of mine and, in the case of Ed, a
close collaborator. The extraordinary con-
vergence and synergy among these inde-
pendent discoveries, collectively saluted by
Science as one of the “breakthroughs-of-
the-year” at the end of 1996 (18), inau-
gurated a new era of AIDS research,
triggering a chain-reaction of additional
breakthroughs which altogether dramati-
cally accelerated our understanding of HIV
physiology and pathogenesis, and posed
the foundations for new therapeutic and
preventive strategies with far-reaching con-
sequences for the ultimate control of the
HIV/AIDS pandemic.
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